Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2019

View Archived Issues

CD7 could target CAR T cells to AML

Long life in the SLO lane

Cross-species analysis identifies NSD2 as a key regulator of metastatic prostate cancer progression

Design and synthesis of novel imidazole-biaryl-tetrazole-based GSNOR inhibitors for COPD

Preclinical data presented for sarecycline for the treatment of acne vulgaris

Roche presents cannabinoid CB2 receptor inverse agonists

Phase III JEWEL study of lurasidone meets primary endpoint in patients with schizophrenia

Pfizer identifies muscarinic M4 receptor PAMs

Takeda Pharmaceutical divulges muscarinic M1 receptor PAMs

Common mechanism links diverse anemias

Protagonist Therapeutics initiates phase II study of PTG-300 in patients with beta-thalassemia

Bristol-Myers Squibb presents phase II data for pegbelfermin in non-alcoholic steatohepatitis

Patient enrollment ongoing in first in human trial of CPI-100

Novel piperazinyl pyrrolidin-2-ones reversibly inhibiting MGL

Blade Therapeutics patents calpain inhibitors

Regulator of calcineurin 1 suppresses nonshivering thermogenesis by two different mechanisms

First subject dosed in phase I study of the anti-AXL antibody BGB-149

Mitokinin discloses new PINK1 modulators

Pluristem reports successful case study in treatment of Buerger's disease patient

miRagen Therapeutics reports new phase I data on cobomarsen in CTCL, ATLL and DLBCL

OncoImmune completes phase II study of CD24Fc for acute GvHD prophylaxis

Beijing InnoCare begins first-in-human study of ICP-192 in advanced solid tumors

Theravance opens phase III study of TD-9855 to treat symptomatic neurogenic orthostatic hypotension

Regeneron initiates phase I/II study of REGN-5458 in relapsed or refractory multiple myeloma

First-in-human trial investigates RIPK1 inhibitor GSK-3145095 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...